The GLP1RAs, dulaglutide, exenatide, semaglutide, liraglutide, tirzepatide, and lixisenatide are FDAapproved for use in the treatment of obesity and type 2 diabetes mellitus (DM), particularly to reduce cardiovascular risk and improve glycemic control.1,2,3 GLP1RAs work by mimicking glucagon-like peptide-1 (GLP-1), an incretin, that functions to subdue appetite, delay gastric emptying, and regulate homeostasis of glucose
2025 Deciding between prescription drops and injections for GLP-1 therapy can feel overwhelming, especially when you want safe, medically supervised care from home
It'll be interesting, though, to see whether fewer do in the future since younger adults are starting therapy (and highly effective therapy for that matter) before those conditions manifest
The compositions of these media are listed in Supplementary Table 2
She is the author of Pregnancy with Type 1 Diabetes, Dealing with Diabetes
Excess fat storage in the liver worsens metabolic dysfunction, creating a vicious cycle